

Maria E Suarez-Almazor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/182408/publications.pdf>

Version: 2024-02-01

142
papers

11,237
citations

76294

40
h-index

34964

98
g-index

146
all docs

146
docs citations

146
times ranked

13552
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691
2	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 625-639.	1.5	1,413
3	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
4	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	0.8	580
5	Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. <i>PLoS ONE</i> , 2016, 11, e0160221.	1.1	373
6	Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. <i>Annals of Internal Medicine</i> , 2018, 168, 121.	2.0	341
7	Determinants of Function After Total Knee Arthroplasty. <i>Physical Therapy</i> , 2003, 83, 696-706.	1.1	223
8	Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. , 2019, 7, 2.		213
9	Mortality and Institutionalization Following Hip Fracture. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 283-288.	1.3	211
10	Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106.		203
11	Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319.		164
12	A randomized controlled trial of acupuncture for osteoarthritis of the knee: Effects of patient-provider communication. <i>Arthritis Care and Research</i> , 2010, 62, 1229-1236.	1.5	156
13	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018, 36, 638-646.	1.2	149
14	Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2061-2064.	0.5	141
15	Psychosocial determinants of outcomes in knee replacement. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1775-1781.	0.5	139
16	Ethnic Variation in Knee Replacement. <i>Archives of Internal Medicine</i> , 2005, 165, 1117.	4.3	137
17	Methotrexate for treating rheumatoid arthritis. <i>The Cochrane Library</i> , 2014, 2014, CD000957.	1.5	134
18	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.	0.8	121

#	ARTICLE	IF	CITATIONS
19	Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2008, 27, 883-889.	1.0	110
20	Systematic review of case reports of antiphospholipid syndrome following infection. <i>Lupus</i> , 2016, 25, 1520-1531.	0.8	105
21	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013, 3, e003563.	0.8	104
22	Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. <i>Arthritis and Rheumatology</i> , 2017, 69, 687-699.	2.9	101
23	Calcium and vitamin D for corticosteroid-induced osteoporosis. <i>The Cochrane Library</i> , 1998, , CD000952.	1.5	93
24	Electronic Monitoring of Oral Therapies in Ethnically Diverse and Economically Disadvantaged Patients With Rheumatoid Arthritis: Consequences of Low Adherence. <i>Arthritis and Rheumatism</i> , 2013, 65, 1421-1429.	6.7	92
25	Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2012, 20, 2985-2998.	1.0	90
26	Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Nutrients</i> , 2017, 9, 42.	1.7	90
27	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018, 36, 601-607.	1.2	90
28	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 736-740.	1.6	90
29	Attitudes of Terminally Ill Cancer Patients About Euthanasia and Assisted Suicide: Predominance of Psychosocial Determinants and Beliefs Over Symptom Distress and Subsequent Survival. <i>Journal of Clinical Oncology</i> , 2002, 20, 2134-2141.	0.8	84
30	Disease and symptom burden in systemic sclerosis: a patient perspective. <i>Journal of Rheumatology</i> , 2007, 34, 1718-26.	1.0	77
31	Impact of educational and patient decision aids on decisional conflict associated with total knee arthroplasty. <i>Arthritis Care and Research</i> , 2012, 64, 229-237.	1.5	76
32	Patterns and Predictors of Unplanned Hospitalization in a Population-Based Cohort of Elderly Patients With GI Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3527-3533.	0.8	72
33	Improving treatment adherence in patients with rheumatoid arthritis: what are the options?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 345-356.	0.3	66
34	Cost-Effectiveness of Total Knee Replacement: A Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2014, 66, 592-599.	1.5	62
35	A Qualitative Analysis of Decision-Making for Total Knee Replacement in Patients With Osteoarthritis. <i>Journal of Clinical Rheumatology</i> , 2010, 16, 158-163.	0.5	56
36	Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Arthritis and Rheumatology</i> , 2021, 73, 866-874.	2.9	56

#	ARTICLE	IF	CITATIONS
37	A systematic review of the effect of TNF- α antagonists on lipid profiles in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2010, 29, 947-955.	1.0	55
38	Identification of rheumatoid arthritis patients using an administrative database: A Veterans Affairs study. <i>Arthritis Care and Research</i> , 2012, 64, 1490-1496.	1.5	55
39	Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. <i>Rheumatology</i> , 2019, 58, vii40-vii48.	0.9	49
40	Acupuncture in the Treatment of Rheumatic Diseases. <i>Current Rheumatology Reports</i> , 2012, 14, 589-597.	2.1	47
41	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 5, CD012657.	1.5	47
42	Adverse Events in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 155-174.	0.8	45
43	Problems in transition and quality of care: perspectives of breast cancer survivors. <i>Supportive Care in Cancer</i> , 2011, 19, 1921-1929.	1.0	44
44	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 2017, CD012591.	1.5	44
45	Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: A systematic review. <i>Arthritis and Rheumatism</i> , 2008, 59, 1625-1638.	6.7	40
46	Running does not increase symptoms or structural progression in people with knee osteoarthritis: data from the osteoarthritis initiative. <i>Clinical Rheumatology</i> , 2018, 37, 2497-2504.	1.0	38
47	Lipid Paradox in Rheumatoid Arthritis: Changes With Rheumatoid Arthritis Therapies. <i>Current Rheumatology Reports</i> , 2012, 14, 428-437.	2.1	37
48	Arthritis risk with immune checkpoint inhibitor therapy for cancer. <i>Current Opinion in Rheumatology</i> , 2019, 31, 293-299.	2.0	36
49	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970.	5.8	34
50	Assessing information needs and use of online resources for disease self-management in patients with rheumatoid arthritis: a qualitative study. <i>Clinical Rheumatology</i> , 2018, 37, 1791-1797.	1.0	33
51	Validation of the Self-efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1195-1200.	1.5	31
52	Development and Pilot Testing of Multimedia Patient Education Tools for Patients With Knee Osteoarthritis, Osteoporosis, and Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 213-220.	1.5	28
53	Digital Patient Education and Decision Aids. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 245-256.	0.8	28
54	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6129-6143.	1.0	28

#	ARTICLE	IF	CITATIONS
55	Patients' expectations about total knee arthroplasty outcomes. <i>Health Expectations</i> , 2016, 19, 299-308.	1.1	27
56	Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1939-1949.	2.0	27
57	Impact of Rheumatoid Arthritis on the Mortality of Elderly Patients Who Develop Cancer: A Population-Based Study. <i>Arthritis Care and Research</i> , 2017, 69, 75-83.	1.5	26
58	Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. <i>Clinical Rheumatology</i> , 2017, 36, 2121-2128.	1.0	24
59	Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. <i>Trials</i> , 2018, 19, 204.	0.7	23
60	Cancer immunotherapy-related adverse events: causes and challenges. <i>Supportive Care in Cancer</i> , 2020, 28, 6111-6117.	1.0	22
61	A comprehensive scoping review to identify standards for the development of health information resources on the internet. <i>PLoS ONE</i> , 2019, 14, e0218342.	1.1	21
62	Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. <i>Lancet Haematology</i> , 2018, 5, e474-e478.	2.2	20
63	Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer. <i>Arthritis Care and Research</i> , 2020, 72, 309-318.	1.5	20
64	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6119-6128.	1.0	20
65	Is there a role for ginger in the treatment of osteoarthritis?. <i>Arthritis and Rheumatism</i> , 2001, 44, 2461-2462.	6.7	19
66	Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy. <i>Journal of Oncology Practice</i> , 2014, 10, e167-e174.	2.5	19
67	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 699-708.	1.6	19
68	Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial). <i>BMJ Open</i> , 2019, 9, e028517.	0.8	19
69	Cancer and Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 445-462.	0.8	19
70	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 114-122.	0.4	19
71	Systematic review of the methodological quality of controlled trials evaluating Chinese herbal medicine in patients with rheumatoid arthritis. <i>BMJ Open</i> , 2017, 7, e013242.	0.8	18
72	Treating Early Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Direct and Indirect Trial Evidence. <i>Arthritis Care and Research</i> , 2018, 70, 1355-1365.	1.5	18

#	ARTICLE	IF	CITATIONS
73	Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 959-967.	0.8	18
74	Self Report Co-Morbidity and Health Related Quality of Life – A Comparison with Record Based Co-Morbidity Measures. <i>Social Indicators Research</i> , 2004, 66, 213-228.	1.4	17
75	HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center. <i>Journal of Oncology Practice</i> , 2015, 11, 384-390.	2.5	17
76	Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. , 2019, 7, 126.		17
77	Knowledge, beliefs, and concerns about bone health from a systematic review and metanalysis of qualitative studies. <i>PLoS ONE</i> , 2020, 15, e0227765.	1.1	17
78	Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. <i>Blood Advances</i> , 2020, 4, 1746-1755.	2.5	17
79	Cyclophosphamide for treating rheumatoid arthritis. <i>The Cochrane Library</i> , 2000, , .	1.5	16
80	Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 2400-7.	1.0	16
81	Acetaminophen overdose: a little recognized public health threat. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 827-829.	0.9	15
82	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. <i>Supportive Care in Cancer</i> , 2020, 28, 6175-6181.	1.0	15
83	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	1.0	14
84	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818.		14
85	Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. <i>Cancer</i> , 2017, 123, 3367-3376.	2.0	13
86	Comparison of multimedia and printed patient education tools for patients with osteoporosis: a 6-month randomized controlled trial. <i>Osteoporosis International</i> , 2020, 31, 857-866.	1.3	13
87	Association of Serum Folate Levels With Cardiovascular Mortality Among Adults With Rheumatoid Arthritis. <i>JAMA Network Open</i> , 2020, 3, e200100.	2.8	13
88	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	1.6	13
89	Interactions and perceptions of patients with rheumatoid arthritis participating in an online support group. <i>Clinical Rheumatology</i> , 2020, 39, 1775-1782.	1.0	13
90	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , 2017, 44, 1894-1898.	1.0	12

#	ARTICLE	IF	CITATIONS
91	Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy. <i>Supportive Care in Cancer</i> , 2014, 22, 537-544.	1.0	11
92	Effect of Body Mass Index and Psychosocial Traits on Total Knee Replacement Costs in Patients with Osteoarthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1600-1606.	1.0	11
93	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 1916-1919.	1.0	11
94	Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1094-1098.	2.0	11
95	Real-World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 560-570.	0.9	11
96	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	1.0	11
97	Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab. <i>Cancer</i> , 2020, 126, 3929-3938.	2.0	10
98	Randomized Controlled Trial of Patient Education Tools for Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1470-1478.	1.5	10
99	Assessing information needs on bone health in cancer survivors. <i>Journal of Cancer Survivorship</i> , 2016, 10, 480-488.	1.5	9
100	Readmission Patterns After GI Cancer Hospitalizations: The Medical Versus Surgical Patient. <i>Journal of Oncology Practice</i> , 2018, 14, e137-e148.	2.5	9
101	Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 958-966.	1.6	9
102	Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 861-871.	3.1	9
103	Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. <i>Immunotherapy</i> , 2021, 13, 465-475.	1.0	9
104	Modeling changes in health perception following hip fracture. <i>Quality of Life Research</i> , 2001, 10, 651-659.	1.5	8
105	Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. <i>Clinical Rheumatology</i> , 2020, 39, 2943-2950.	1.0	8
106	Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies. <i>Arthritis Care and Research</i> , 2021, 73, 1461-1469.	1.5	8
107	Online Educational Tool to Promote Bone Health in Cancer Survivors. <i>Journal of Health Communication</i> , 2017, 22, 808-817.	1.2	7
108	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1164-1167.	1.0	7

#	ARTICLE	IF	CITATIONS
109	Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer. <i>Clinical Rheumatology</i> , 2020, 39, 787-794.	1.0	7
110	The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature.. <i>Journal of Clinical Oncology</i> , 2018, 36, 41-41.	0.8	7
111	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020, 9, e16799.	0.5	7
112	Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans. <i>Supportive Care in Cancer</i> , 2017, 25, 1571-1577.	1.0	6
113	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1173-1178.	1.0	6
114	Psychosocial Determinants of Total Knee Arthroplasty Outcomes Two Years After Surgery. <i>ACR Open Rheumatology</i> , 2020, 2, 573-581.	0.9	6
115	Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. <i>Arthritis Care and Research</i> , 2021, 73, 649-657.	1.5	6
116	Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 211-213.	1.3	5
117	Cervical Cancer Screening in Women with Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 73, 1796-1803.	1.5	5
118	Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?. <i>Arthritis and Rheumatology</i> , 2019, 71, 1971-1973.	2.9	4
119	Systematic Review of Economic Evaluations of Cycling Versus Swapping Medications in Patients With Rheumatoid Arthritis After Failure to Respond to Tumor Necrosis Factor Inhibitors. <i>Arthritis Care and Research</i> , 2020, 72, 343-352.	1.5	4
120	Evidence that Swimming May Be Protective of Knee Osteoarthritis: Data from the Osteoarthritis Initiative. <i>PM and R</i> , 2020, 12, 529-537.	0.9	4
121	Launching an Electronic Patient-Reported Outcomes Initiative in Real-Time Clinical Practice. <i>Journal of the National Cancer Institute Monographs</i> , 2021, 2021, 23-30.	0.9	4
122	Systemic Lupus Erythematosus and Mortality in Elderly Patients With Early Breast Cancer. <i>Arthritis Care and Research</i> , 2023, 75, 559-568.	1.5	4
123	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1113-1116.	1.6	4
124	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	0.7	4
125	Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 73-83.	0.5	3
126	Derivation and Validation of the Cancer READMIT Score: A Readmission Risk Scoring System for Patients With Solid Tumor Malignancies. <i>JCO Oncology Practice</i> , 2022, 18, e117-e128.	1.4	3

#	ARTICLE	IF	CITATIONS
127	Comorbidities and Myelodysplastic Syndromes.. Blood, 2009, 114, 2789-2789.	0.6	3
128	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot and Feasibility Studies, 2022, 8, 45.	0.5	3
129	A randomized controlled trial evaluating the effects of social networking on chronic disease management in rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2022, 56, 152072.	1.6	3
130	A Randomized Controlled Trial Comparing Two Self-Administered Educational Strategies for Patients With Knee Osteoarthritis. ACR Open Rheumatology, 2021, 3, 185-195.	0.9	2
131	Regulatory issues and economic efficiency. Journal of rheumatology Supplement, The, 2003, 68, 5-7.	2.2	2
132	Training in patient-centered outcomes research for specific researcher communities. Journal of Clinical and Translational Science, 2017, 1, 278-284.	0.3	1
133	Quality appraisal of educational websites about osteoporosis and bone health. Archives of Osteoporosis, 2021, 16, 28.	1.0	1
134	Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index. Blood, 2010, 116, 605-605.	0.6	1
135	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. Journal of Immunotherapy and Precision Oncology, 2022, 5, 26-30.	0.6	1
136	Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group. Seminars in Arthritis and Rheumatism, 2023, 58, 152028.	1.6	1
137	Reply. Arthritis Care and Research, 2020, 72, 1828-1829.	1.5	0
138	Reply. Arthritis and Rheumatology, 2021, 73, 1564-1564.	2.9	0
139	Guest Editorsâ€™ Introduction. Journal of the National Cancer Institute Monographs, 2021, 2021, 1-2.	0.9	0
140	Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment.. Journal of Clinical Oncology, 2018, 36, 67-67.	0.8	0
141	Postoperative Major Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus. ACR Open Rheumatology, 2022, , .	0.9	0
142	Exercise and physical therapy for systemic sclerosis. The Cochrane Library, 2022, 2022, .	1.5	0